Smartwatch with heart rate monitor icon on colorful diagonal striped background
Medtech Case Study

A Patient-Centered Benefit-Risk Framework Supports an Expanded Indication

Use of a Patient-Centered Benefit-Risk Framework to Obtain the First 510(k) Clearance Based in Part on Patient Preference Data
 

Source
Medical Device Innovation Consortium (MDIC)

Link
Using the MDIC Patient-Centered Benefit-Risk Framework to Support an Expanded Indication
 

Description of Case Study

NxStage used patient engagement and patient preference data to support a 510(k) expansion allowing patients to perform home hemodialysis (HHD) independently, without a care partner. The effort was prompted by patient feedback gathered at a Kidney Health Initiative workshop, where patients expressed a desire for greater autonomy and access to home dialysis. To demonstrate that patients understood and were willing to accept the risks of solo HHD, NxStage used MDIC’s Patient-Centered Benefit-Risk Framework to design a quantitative patient preference study. A discrete choice survey assessed the level of risk patients were willing to accept for independent HHD compared with in-center dialysis, generating evidence that informed the US Food and Drug Administration’s (FDA) benefit-risk evaluation for the expanded indication.
 

Quick Facts

Organization name: NxStage
Organization type: large medtech company (250-plus employees)
Product category: therapeutic device or technology
Region(s) of patient engagement activities: North America: United States
Total product life cycle stage(s): evaluation/authorization; post-approval
surveillance/monitoring

 

Product Type(s)

medical devices:

  • home-use device
  • therapeutic device

Product Medical Specialty Area(s)

  • other: nephrology
     

Stakeholders

  • medtech company: internal regulatory affairs teams
  • patients and caregivers, patient organizations
  • regulators
     

Methods and Sources of Patient Input

  • interviews/focus groups/surveys
  • patient preference information/studies
     

Impact of Patient Engagement

The company’s approach to using quantitative patient preference data was successful, resulting in a 510(k) clearance and approval of an expanded indication of solo HHD during waking hours. Survey results showed that not all patients preferred solo HHD given its risks. This guided NxStage’s communications strategy and led to the development of a decision-support tool to help patients and clinicians make informed choices about whether solo HHD was appropriate for a given patient.
 

Lessons Learned

The outcomes indicate the value of learning about and pursuing patient preferences, which can help device manufacturers understand their technology’s benefits and risks, market viability, and usability.

Additional lessons learned included:

  • Assessing whether a patient preference study is truly warranted: Data on patient preferences regarding the benefits and risks of treatment options were not available through clinical studies alone, so developers decided to quantify patient preferences through an additional preference study.
  • Engaging in early dialogue with the FDA is essential to study design: NxStage’s initial plan for a qualitative-only approach was reshaped through pre-submission discussions with the FDA, which clarified the need for statistical rigor. Engaging the FDA early helped the company design a stronger study and ensured the data met regulatory expectations.
  • Leveraging established frameworks to accelerate learning: Consulting MDIC’s Patient-Centered Benefit-Risk Framework helped NxStage understand the available methods, select the right approach, and establish a common vocabulary with FDA reviewers, an important asset for a team that was relatively new to quantitative patient preference science.